Every material Form 8-K Jaguar Health, Inc. has filed with the SEC since October 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Jaguar Health held a special meeting of stockholders on November 6, 2026, and all six proposals were approved. The approvals cover a reverse stock split at a ratio between 1-for-2 and 1-for-150, to be set by the board, and a reduction in the floor price of an equity line agreement with C/M Capital from $16.50 to $1.10 per share. The reverse split was approved under the Votes Cast Standard but not under the Majority of Outstanding Standard, as the filing notes.
Special meeting held November 6, 2026; 3,383,169 of 7,802,102 shares of common stock outstanding as of the September 15, 2026 record date were represented.
Reverse stock split approved at a ratio of not less than 1-for-2 and not greater than 1-for-150; the board will set the exact ratio and announce it within one year.
Reverse split vote was 3,551,428 for and 222,394 against, but not approved under the Majority of Outstanding Standard.
ELOC Agreement floor price cut from $16.50 to $1.10 per share; 2,400,107 votes for and 158,386 against.
Jaguar Health disclosed that on November 2, 2026, each outstanding share of its Series R Convertible Preferred Stock automatically converted into five shares of common stock. Immediately after the conversion, 13,345,986 common shares were issued and outstanding, and holders of eligible warrants may receive up to 69,823 more common shares upon exercise. The filing is administrative in nature and does not report revenue, profit, or guidance.
Series R Preferred Stock converted into common stock on November 2, 2026, at five common shares per preferred share
13,345,986 shares of common stock outstanding immediately after the conversion
Eligible warrants may be exercised for up to 69,823 common shares, including the Series O preferred dividend and Series R dividend shares
Special dividend of Series O preferred stock was paid on October 15, 2026, to holders of record on October 13, 2026
Jaguar Health filed a supplement to its proxy statement for the November 6, 2026 special meeting, disclosing a six-fold increase in shares available under its 2014 Stock Incentive Plan. The adjustment offsets dilution from the Series R Preferred Stock dividend and conversion, and it takes effect after the meeting if stockholders approve Proposal 3. Shareholders should note that the filing does not change the proposals or the board's recommendations.
Share Reserve Adjustment raises 2014 Plan shares to 2,273,154 if Proposal 3 is approved, up from 378,859 proposed in the proxy statement
Without approval, the 2014 Plan would have 4,260 shares available, up from 710 shares, per the filing
Series R Preferred Stock converts to five common shares per preferred share on November 2, 2026
Jaguar Health's board declared a special stock dividend of Series R Convertible Preferred Stock, with a record date of October 13, 2026, and conversion into common stock on November 2, 2026. The filing says the conversion could issue up to 11,406,235 common shares, about 83.3% of common stock outstanding afterward, which would significantly dilute holders who do not receive the dividend. The company also moved the start of royalty payments and the 2021 note maturity from October 1, 2026 to January 1, 2027, and agreed to repurchase Series P preferred stock in cash on a fundamental transaction.
Record date October 13, 2026; payment date October 15, 2026; each Series R share converts into five common shares on November 2, 2026.
Filing estimates up to 11,406,235 common shares on conversion, about 83.3% of common outstanding, based on 2,138,712 shares outstanding as of October 1, 2026 and full warrant exercise.
Royalty payments to Uptown and Streeterville, each a $12 million royalty interest, now start January 1, 2027, with a monthly minimum of $750,000.
The 2021 $6,220,812.50 note maturity moved to January 1, 2027; Series R shares have no voting rights and a nominal $0.0001 per share liquidation preference.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Jaguar Health, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →